This inventor holds 2 USPTO granted patents. Top assignee: Kowa Company Limited. Active years: 1987-1988.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1987-1988
Title: Kouji Ikegaya: Innovator in Pharmaceutical Composition
Introduction
Kouji Ikegaya is a notable inventor based in Higashimurayama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions suitable for intestinal administration. With a total of 2 patents to his name, Ikegaya's work is recognized for its potential impact on drug delivery systems.
Latest Patents
Ikegaya's latest patents focus on a pharmaceutical composition that comprises a physiologically active substance possessing peptide bonds in its structure. This substance is inactivable by digestive enzymes and is designed to enhance intestinal absorption. The composition is particularly noteworthy as it includes a synthetic chymotrypsin inhibitor, which aids in the effective delivery of the active substance, excluding insulin.
Career Highlights
Throughout his career, Kouji Ikegaya has been associated with Kowa Company Limited, where he has contributed to innovative research and development in pharmaceuticals. His expertise in creating effective drug formulations has positioned him as a key figure in the industry.
Collaborations
Ikegaya has worked alongside esteemed colleagues such as Setsuro Fujii and Touru Yokoyama. Their collaborative efforts have further advanced the research and development of pharmaceutical compositions.
Conclusion
Kouji Ikegaya's contributions to pharmaceutical innovation highlight his dedication to improving drug delivery systems. His patents reflect a commitment to enhancing patient care through effective medication administration.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
